Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Pharma CoROCO:4166 +0.41%70 Debt-to-Equity is 0.07 as of Jun. 2026, which is 75% below its 10-year median of 0.28. GuruFocus rates ROCO:4166 with a GF Score™ of 70/100 and a GF Value™ of NT$41.29 (Significantly Undervalued). Among 811 Drug Manufacturers companies, Orient Pharma Co ranks better than 77.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Orient Pharma Co's Debt-to-Equity or its related term are showing as below:
ROCO:4166'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.28 Max: 0.47
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Orient Pharma Co was 0.47. The lowest was 0.07. And the median was 0.28.
ROCO:4166's Debt-to-Equity is ranked better than 77.44% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ROCO:4166: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Orient Pharma Co Debt-to-Equity Related Terms
Orient Pharma Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Debt-to-Equity of 0.07 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orient Pharma Co and its competitors. This is 75% below median its historical median of 0.28. Over the past decade, Orient Pharma Co's Debt-to-Equity has ranged from 0.07 to 0.47. According to the industry distribution chart, Orient Pharma Co ranks #183 out of 811 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Orient Pharma Co's Debt-to-Equity too high?
Orient Pharma Co's current Debt-to-Equity of 0.07 is 75% below median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.47. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Orient Pharma Co's value of 0.07 is 74.1% below this industry median. Based on the distribution chart, Orient Pharma Co ranks #183 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Pharma Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #183 out of 811 companies for Debt-to-Equity. This places Orient Pharma Co in the top 23% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Orient Pharma Co's value of 0.07 is 74.1% below this benchmark. Historically, Orient Pharma Co's own Debt-to-Equity has ranged from 0.07 to 0.47 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 0.27, Orient Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Debt-to-Equity of 0.07 is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Debt-to-Equity is 0.07, which is 75% below median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$41.29, compared to a current price of NT$24.50 — trading 40.7% below its estimated fair value. The current Debt-to-Equity is 0.07, which is 75% below median its 10-year median of 0.28 and 74.1% below the Drug Manufacturers industry median of 0.27. Orient Pharma Co's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Debt-to-Equity is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$24.50 is trading 40.7% below its estimated GF Value™ of NT$41.29.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Debt-to-Equity: 0.07 (75% below median its 10-year median of 0.28)
GF Value™: NT$41.29 vs. price of NT$24.50 (40.7% below fair value)
Industry Position: 74.1% below the Drug Manufacturers median (#183 of 811)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:4166
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
